Utility of the percentage of positive prostate biopsies in predicting PSA outcome after radiotherapy for patients with clinically localized prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 4, 2003, Pages 963-967

  Selek, Ugur ^a   Lee, Andrew ^a   Levy, Lawrence ^a   Kuban, Deborah A ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Biopsy; Outcome; Prostate cancer; Prostate specific antigen; Radiotherapy

Indexed keywords

ANTIGENS; BIOPSY; DOSIMETRY; RADIOTHERAPY; TUMORS;

LOCALIZED PROSTATE CANCERS;

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; RADIATION DOSE; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0142217889     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00748-X     Document Type: Article

References (31)

1. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 280:1998;969-974.
2. Sebo T.J., Bock B.J., Cheville J.C., et al. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol. 163:2000;174-178.
3. Terris M.K., Haney D.J., Johnstone I.M., et al. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systematic sextant biopsies. Urology. 45:1995;75-80.
4. Badalament R.A., Miller M.C., Peller P.A., et al. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol. 156:1996;1375-1380.
5. Borirakchanyavat S., Bhargava V., Shinohara K., et al. Systematic sextant biopsies in the prediction of extracapsular extension at radical prostatectomy. Urology. 50:1997;373-378.
6. D'Amico A.V., Whittington R., Malcowicz S.B. A multivariate analysis evaluating the role of percent positive biopsies and endorectal coil MRI in predicting extraprostatic disease and time to postoperative PSA failure in intermediate risk prostate cancer patients. Cancer J. 2:1996;343-350.
7. Conrad S., Graefen M., Pichlmeier U., et al. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. J Urol. 159:1998;2023-2029.
8. Lee A.K., Schultz D., Renshaw A.A., et al. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys. 49:2001;673-677.
9. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol. 18:2000;1164-1172.
10. Ravery V., Chastang C., Toublanc M., et al. Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer. Eur Urol. 37:2000;449-455.
11. D'Amico A.V., Schultz D., Silver B., et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 49:2001;679-684.
12. Gleason D.F. Histologic grading and staging of prostatic carcinoma. 1977;Lea & Febiger, Philadelphia.
13. Beahrs O.H. Manual for staging of cancer. 4th ed:1992;Lippincott, Philadelphia.
14. Neter J., Wasserman W., Kutner M.H. Applied linear regression models. 1983;R. D. Irwin, Homewood, IL.
15. Consensus statement Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
16. Zagars G.K., Pollack A., Kavadi V.S., et al. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;293-306.
17. Pisansky T.M., Kahn M.J., Rasp G.M., et al. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer. 79:1997;337-344.
18. Lee W.R., Hanks G.E., Schultheiss T.E., et al. Localized prostate cancer treated by external-beam radiotherapy alone Serum prostate-specific antigen-driven outcome analysis. J Clin Oncol. 13:1995;464-469.
19. Pisansky T.M., Cha S.S., Earle J.D., et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol. 11:1993;2158-2166.
20. Zietman A.L., Coen J.J., Shipley W.U., et al. Radical radiation therapy in the management of prostatic adenocarcinoma The initial prostate specific antigen value as a predictor of treatment outcome. J Urol. 151:1994;640-645.
21. Hanks G.E., Lee W.R., Schultheiss T.E. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol. 154:1995;456-459.
22. Partin A.W., Piantadosi S., Sanda M.G., et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology. 45:1995;831-838.
23. D'Amico A.V., Whittington R., Schultz D., et al. Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol. 158:1997;1422-1426.
24. Ragde H., Blasko J.C., Grimm P.D., et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 80:1997;442-453.
25. 125iodine implantation for stage T1/T2 prostatic carcinoma. J Urol. 154:1995;1096-1099.
26. Wallner K., Roy J., Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
27. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;447-457.
28. Altman D.G., De Stavola B.L., Love S.B., et al. Review of survival analyses published in cancer journals. Br J Cancer. 72:1995;511-518.
29. Grossfeld G.D., Chang J.J., Broering J.M., et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy Results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol. 165:2001;851-856.
30. Pollack A., Zagars G.K., Smith L.G., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 18:2000;3904-3911.
31. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 53:2002;1097-1105.